KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShort-Term Debt issuances
Ratios

Astrazeneca (AZN) Short-Term Debt issuances (2019 - 2025)

Historic Short-Term Debt issuances for Astrazeneca (AZN) over the last 7 years, with Q4 2025 value amounting to -$29.6 billion.

  • Astrazeneca's Short-Term Debt issuances rose 222.15% to -$29.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$29.6 billion, marking a year-over-year increase of 222.15%. This contributed to the annual value of -$29.6 billion for FY2025, which is 222.15% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Short-Term Debt issuances is -$29.6 billion, which was up 222.15% from -$32.6 billion recorded in Q3 2025.
  • Astrazeneca's 5-year Short-Term Debt issuances high stood at -$399.0 million for Q1 2021, and its period low was -$34.6 billion during Q1 2024.
  • For the 5-year period, Astrazeneca's Short-Term Debt issuances averaged around -$28.3 billion, with its median value being -$30.7 billion (2022).
  • Its Short-Term Debt issuances has fluctuated over the past 5 years, first soared by 848.62% in 2021, then crashed by 769423.56% in 2022.
  • Astrazeneca's Short-Term Debt issuances (Quarter) stood at -$399.0 million in 2021, then plummeted by 7226.32% to -$29.2 billion in 2022, then grew by 2.09% to -$28.6 billion in 2023, then dropped by 5.85% to -$30.3 billion in 2024, then increased by 2.22% to -$29.6 billion in 2025.
  • Its last three reported values are -$29.6 billion in Q4 2025, -$32.6 billion for Q3 2025, and -$31.6 billion during Q1 2025.